

METH'S PATENTED SOLUTION


Warner-Lambert Co. and its new owner, Pfizer, hold a patent on an improved cold pill that cannot be made into the street drug methamphetamine. Because of cost, however, Pfizer has not pursued the clinical trials in humans needed to bring the product to market.

STAKING THE CLAIM

The company first filed for a provisional patent for the new drug in July 1998, and a full patent was issued Dec. 17, 2002.

A NEW DRUG

Warner-Lambert cited among the benefits of the new drug its inability to make the potent stimulant. Tests on animals showed that this new pseudoephedrine causes fewer side effects than the existing molecule in Sudafed and other decongestants.



20 (+)-Pseudoephedrine is known as a decongestant, but it can readily be converted into the psychoactive drug, (S)-methamphetamine, by reduction of the hydroxyl group to hydrogen. Reduction of the hydroxyl in (-)-pseudoephedrine yields a compound with only one-tenth the psychoactivity of (S)-methamphetamine. Hence, the present compositions and methods avoid this problem.

25


The term "substantially free of (+)-pseudoephedrine" means that the composition contains at least 99% pseudoephedrine and 10% or less of (+)-pseudoephedrine.

Excerpts from the original patent

REWRITING THE MOLECULAR CODE

The new pseudoephedrine is a mirror image of the existing molecule. Cooking meth with the new molecule would result in a benign drug with only minor stimulant effects.

Existing pseudoephedrine molecule



Mirror Image

New pseudoephedrine molecule

